The Lancet on the anti-IL-5 antibody mepolizumab in individuals with allergic asthma, evidence has accumulated that the pathogenetic role of eosinophils is fundamentally different between asthma ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...

Credit: Toa55/Shutterstock. The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a ...

Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in ...

Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion. Blueprint shareholders also will receive one ...

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare immunological disease, and other ...

French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of the Cambridge, Mass.-based biopharma firm soaring in intraday trading.

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US ...